Morphine (Sulfate) Lavoisier (Morphine Sulfate)

Morphine acts on the opioid pathway to provide potent analgesia for severe pain conditions.

• Severe acute pain: rapid relief of intense short‑term pain such as postoperative or traumatic injury.
• Chronic cancer pain: sustained control of persistent pain associated with malignant disease.
• Palliative care pain: alleviation of severe discomfort in end‑of‑life settings.
• Procedural pain: analgesia during invasive diagnostic or therapeutic procedures.

• Morphine is a full agonist at the μ‑opioid receptors located in the central nervous system and spinal cord. Binding activates inhibitory G‑protein pathways, reducing neuronal excitability, decreasing the release of excitatory neurotransmitters, and modulating pain signal transmission. This results in pronounced analgesic effects and altered perception of pain. The drug also influences descending pain pathways and can produce sedation and respiratory depression as part of its central actions.

Morphine may cause a range of adverse reactions, varying from common to serious.

Common Side Effects

• Nausea
• Constipation
• Drowsiness or sedation
• Sweating

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Dependence or addiction

When using morphine, careful clinical assessment and monitoring are essential.

• Assess respiratory function: monitor for depression, especially in opioid‑naïve patients.
• Evaluate renal and hepatic function: adjust use in impairment.
• Use caution in the elderly: increased sensitivity to sedative effects.
• Avoid concomitant CNS depressants: heightened risk of respiratory compromise.
• Monitor for signs of dependence: implement appropriate risk‑mitigation strategies.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Morphine interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
• Monoamine oxidase inhibitors: risk of severe opioid toxicity.
• Other opioids: additive effects increase risk of overdose.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise morphine plasma levels.
• Diuretics: can enhance hypotensive effects.
• Serotonergic agents (e.g., SSRIs, tramadol): potential for serotonin syndrome.